Hybrid thoracoscopic surgical and transvenous catheter ablation versus transvenous catheter ablation in persistent and longstanding persistent atrial fibrillation (HARTCAP-AF): study protocol for a randomized trial

Mindy Vroomen1,3*, Mark La Meir2,4, Bart Maesen2,3, Justin G. L. Luermans1,3, Kevin Vernooy1,3, Brigitte Essers5, Bianca T. A. de Greef6, Jos G. Maessen2,3, Harry J. Crijns1,3 and Laurent Pison1,3

Abstract

Background: Success rates with conventional transvenous endocardial pulmonary vein isolation in patients with persistent and longstanding persistent atrial fibrillation (AF) are variable due to advanced electrical and structural remodeling of the atria. As a consequence, more extensive endocardial lesions, minimally invasive thoracoscopic surgical techniques, and hybrid ablation (combining thoracoscopic epicardial surgical and endocardial catheter ablation) have been developed.

Hypothesis: The HARTCAP-AF trial hypothesizes that hybrid AF ablation is more effective than (repeated) transvenous endocardial catheter ablation in (longstanding) persistent AF, without increasing the number of associated major adverse events.

Methods: This randomized controlled trial will include 40 patients with persistent or longstanding persistent AF who will be 1:1 randomized to either hybrid ablation or (repeated) catheter ablation. The procedures and follow-up are conducted according to the guidelines. The primary effectiveness endpoint is freedom from any supraventricular arrhythmia lasting longer than 5 min without the use of Vaughan-Williams class I or III antiarrhythmic drugs through 12 months of follow-up after the last procedure. In the catheter ablation arm, a second procedure planned within 6 months after the index procedure is allowed for obtaining the primary endpoint. Additionally, adverse events, cost-effectiveness, and quality of life data will be recorded.

Trial registration: ClinicalTrials.gov, NCT02441738. Registered on 12 May 2015.

Keywords: Atrial fibrillation, Persistent, Longstanding persistent, Hybrid ablation, Catheter ablation

* Correspondence: mindyvroomen1@gmail.com
1Department of Cardiology, Maastricht University Medical Centre, PO Box 5800, Maastricht, The Netherlands
2Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands
3Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Transvenous endocardial catheter ablation for pulmonary vein isolation (PVI) is the standard treatment option for patients with symptomatic paroxysmal atrial fibrillation (AF). Unfortunately, single procedural results of this technique in (longstanding) persistent AF are less convincing [1–5]. Due to advanced electrical and structural remodeling in these patients with nonparoxysmal AF, a more extensive lesion set might be required to achieve rhythm control. Multiple techniques have been introduced, including ablation of complex fractionated atrial electrograms (CFAE) [4–6], the application of linear lesions [4, 7–9], rotor ablation [10], or a combination of techniques in the so-called stepwise approach [11–15]. However, reported results are highly variable. One of the major limitations seems to be the availability of percutaneous devices able to reliably create transmural lesions [16].

While surgical techniques have proven to be more efficacious in overcoming this limitation [17], approaches such as the Cox-Maze procedure are considered too invasive and complex and therefore have never been widely adopted. This has led to the development of minimally invasive thoracoscopic surgical techniques and hybrid ablation. In hybrid ablation, consisting of a combination of thoracoscopic epicardial surgical and endocardial catheter ablation, surgeons and electrophysiologists combine their expertise to maximize success rates and minimize procedural complications [18]. However, the question of which lesion sets should be used in patients with nonparoxysmal AF remains unanswered. The HRS/EHRA/ECAS expert consensus statement [19] and the guidelines of the Society of Thoracic Surgeons [20] recommend considering additional ablation lesions besides PVI, but do not specify which strategy to use due to a lack of evidence. Therefore, research to identify the most appropriate lesion set and ablation technique is critical to improve results in these patients.

Currently, there is lack of clinical data comparing different ablation strategies in the treatment of nonparoxysmal AF. It is the aim of the present study to compare the safety, efficacy, and cost-effectiveness of hybrid ablation (performed in one stage) versus transvenous endocardial catheter ablation (allowing repeated ablation procedures).

Methods
Design and hypothesis
This is a prospective, randomized trial conducted at the Maastricht University Medical Centre, Maastricht, the Netherlands. The study objective is to compare the efficacy and safety of two interventional approaches for symptomatic, drug refractory persistent or longstanding persistent AF. A total of 40 eligible patients will be randomized (in a 1:1 ratio) to the following treatment arms: 1) a hybrid ablation arm (n = 20 patients), a one-stage hybrid procedure consisting of surgical thoracoscopic epicardial ablation combined with endocardial catheter ablation; or 2) a catheter ablation arm (n = 20 patients), consisting of conventional endocardial catheter ablation, followed by repeated catheter ablation if clinically indicated and decided within 6 months after the initial procedure.

The primary and secondary effectiveness endpoints are shown in Table 1. A blanking period of 3 months is applied. A second ablation after the hybrid ablation and a decision for redo-ablation beyond 180 days after the index catheter ablation will be considered a failure. A third catheter ablation at any time will also be considered a failure in the catheter arm. While the current guidelines define failure as a recurrence of >30 s, failure in the primary endpoint of this study is defined as a recurrence of >5 min [19, 21]. This allows us to reliably evaluate various Holter examinations and this reflects a more clinical endpoint compared with >30 s, since it has been shown that the presence of AF episodes >30 s do not predict clinically meaningful AF, and that quality of life is mainly negatively influenced in patients with a high symptomatic AF burden [22, 23]. The primary and secondary safety endpoints are shown in Table 2.

This study hypothesizes that a one-stage hybrid ablation will have greater clinical effectiveness during long-term follow-up compared with (repeated) endocardial catheter ablation in patients with (longstanding) persistent AF, without increasing the number of associated major adverse events.

Inclusion criteria
All patients (male and female, aged >18 years, mentally able and willing to give informed consent) with symptomatic persistent or longstanding persistent AF refractory or intolerant to at least one Vaughan-Williams class I or III antiarrhythmic drug (AAD) who are able and willing to receive all of the study-related procedures are eligible for enrolment in this trial.

Exclusion criteria
Potential subjects will be excluded from the study if any of the conditions shown in Table 3 apply.

Randomization
Randomization will be performed directly after written informed consent is obtained by the Clinical Trial Center Maastricht using the ALEA software program (FormsVision BV, Abcoude, the Netherlands). This software is programmed to equally distribute the number of patients over the two groups so that an even number of patients are treated with either catheter or hybrid ablation. The randomization is block designed and restricted (stratified; the type of AF (persistent or longstanding AF) will be taken into account to ensure a good balance of patient characteristics in both groups. Using this randomization method, allocation concealment is guaranteed. For every patient that withdraws their consent
before the ablation is performed, an additional patient will be randomized.

**Pre-procedural investigations**
Pre-procedural investigations include physical examination, 12-lead electrocardiogram (ECG), blood analysis (e.g., hemoglobin, C-reactive protein, creatinine), transthoracic echocardiography, a lung function test, and a standard computed tomography (CT) scan. Patients older than 60 years and patients with an elevated cardiovascular risk profile (i.e., family history of cardiovascular disease, elevated body mass index, diabetes, dyslipidemia, hypertension, or smoking) will undergo a cardiac CT scan or coronary angiogram. In addition, quality of life (using the EQ-5D-5 L questionnaire) is assessed at baseline.

**Intervention: transvenous catheter ablation**
This ablation procedure is conducted while the patient is under sedation or general anesthesia. At the beginning of the procedure, a transesophageal echo is performed to confirm the absence of intracardiac thrombi. A His bundle (St. Jude Medical, St. Paul, Minnesota) and coronary sinus catheter (Medtronic, Minneapolis, Minnesota) are placed under fluoroscopy. Access to the left atrium is achieved via a femoral approach and double transseptal puncture. A single bolus of 100 IU/kg bodyweight of heparin is administered, followed by a heparin perfusor to maintain an activated clotting time above 300 s. An electroanatomical map of the left atrium is created using a mapping catheter (Lasso or Pentaray, Biosense Webster, Diamond Bar, California) with direct visualization on a three-dimensional mapping system (Carto, Biosense Webster). The ablation is performed using an irrigated tip contact force radiofrequency (RF) ablation catheter (ThermoCool Smarttouch, Biosense Webster). Automated lesion tagging (VisiTag, Biosense Webster) is used to mark the location of each ablation lesion. The power setting used is 25–30 W with an ablation index of 400 at the posterior wall, and 30–35 W with an ablation index of 500 at the anterior wall and other regions of the left atrium. The minimum lesion set that has to be performed is PVI and a superior and inferior connecting line (box lesion) (Fig. 1). In cases of a documented right atrial flutter (AFL), AFL induced during the ablation, or a dilated right atrium (> 25

| Table 1 Effectiveness endpoints |
|---------------------------------|
| **Primary Effectiveness Endpoint** |
| Freedom from any documented supraventricular arrhythmia (i.e. AF, AFL, AT) lasting > 5 minutes\(^1\), without the use of Vaughan-Williams class I or III AAD, through 12 months of follow-up\(^2\) |
| **Secondary Effectiveness Endpoints** |
| Freedom from any documented supraventricular arrhythmia (i.e. AF, AFL, AT) lasting > 5 minutes, without the use of AAD class I or III, through 36 months of follow-up\(^3\) |
| Freedom from any documented supraventricular arrhythmia lasting ≥ 30 seconds without the use of AAD class I or III\(^3\) |
| Freedom from any documented supraventricular arrhythmia, both ≥ 30 seconds and > 5 minutes\(^2\) |
| Freedom from AAD class I and III\(^3\) |
| Numbers of cardioversions and reinterventions\(^3\) |
| Number of arrhythmia related hospital admissions\(^3\) |
| Quality of life\(^3\) |
| Cost-effectiveness\(^3\) |

AF = Atrial Fibrillation, AFL = Atrial Flutter, AT = Atrial Tachycardia, AAD = Antiarrhythmic drugs.

\(^1\)While the current definitions of failure as proposed by recent guidelines are used as secondary efficacy endpoint in this protocol, the primary endpoint is freedom of recurrences >5 minutes since this reflects a more clinical endpoint compared to >30 seconds, and also allows to reliably evaluate various Holter modalities for prolonged monitoring. \(^2\) After the predefined ablation procedure(s) and considering a 3 months blanking period. \(^3\) Through 12 and 36 months of follow-up after the predefined ablation procedure(s).
In the event of an eventual second study ablation, the lesions made in the initial ablation are checked for conduction gaps and re-ablated as needed. Additional lesions are added, if necessary, at the electrophysiologist's discretion.

Intervention: hybrid ablation

At the beginning of this procedure a transesophageal echo is performed to confirm the absence of intracardiac thrombi. Surgical epicardial ablation is performed while the patient is under general anesthesia, with double-lumen endotracheal intubation using video-assisted thoracoscopic surgery on the beating heart. Access is gained through small incisions in the intercostal spaces. On the right side, the pericardial sac is opened parallel and ventral to the phrenic nerve. The pericardial reflections around both caval veins are dissected to provide access to the transverse and oblique pericardial sinuses. The right pulmonary veins are isolated using a bipolar RF clamp (Synergy System, Atricure Inc., Cincinnati, OH, USA). The right-sided parts of the superior and inferior line are created using a bipolar unidirectional RF device (Coolrail, Atricure Inc., Cincinnati, OH, USA). On the left side, a similar procedure is performed. This box lesion is the epicardial lesion set in all patients regardless of their type of AF (Fig. 2).

In case of incomplete lesions, conduction gaps are completed endocardially. In case of a documented right AFL, AFL induced during ablation, or a dilated right atrium (> 25 mL/m² in men, > 21 mL/m² in women), a CTI line is performed endocardially. Additional endocardial lesions can be added, if necessary, at the hybrid ablation procedures.

### Table 2 Effectiveness endpoints

| Primary Safety Endpoint | Secondary Safety Endpoints |
|-------------------------|-----------------------------|
| A composite of major adverse events and complications occurring through 12 months of follow-up, comprising: |
| Death |
| TIA or CVA |
| Cardiac tamponade/perforation |
| Myocardial infarction |
| Pneumothorax requiring intervention (after removal of chest tubes) |
| Bleeding requiring transfusion/re-operation |
| Gastroparesis |
| Empyema |
| Symptomatic PV stenosis > 70% |
| Pericarditis¹ |
| Symptomatic persistent diaphragmatic paresis/paralysis |

| All major complications occurring through 36 months of follow-up | Minor complications (Superficial wound infections, pneumonia, vascular access complications)² |
|-----------------------------|-----------------------------|
| Pacemaker implantation² | Cumulative procedural radiation exposure time and dosage² |
| Number of (Serious) Adverse Events² | Cumulative procedure time² |

TIA = Transient Ischemic Attack, CVA = Cerebro Vascular Accident, PV = Pulmonary Vein. ¹ Leading to hemodynamic comprises or requiring pericardiocentesis or necessitating (prolongation of) hospital admission.

²Through 12 and 36 months of follow-up after the predefined ablation procedures.
physician’s discretion. If the patient is still in AF at the end of the procedure, the patient is electrically or pharmacologically cardioverted.

**Follow-up**
Patients are seen at the outpatient clinic 3, 6, 12, 24, and 36 months after the predefined ablation procedures. At all visits the heart rhythm will be determined according to the HRS/EHRA/ECAS expert statement [24], which includes an ECG in case of symptoms and at each visit, 24-h Holter examination at 3 and 6 months, and a 7-day Holter examination at the remaining visits. Furthermore, in case of an absence of symptoms on the ECG, Holter examinations are performed. The Holter examinations are assessed by nonblinded but independent Holter specialists. At 12 and 36 months, quality of life (using the EQ-5D-5 L questionnaire) is re-assessed (Fig. 3). The SPIRIT checklists are presented in Fig. 4 and Additional file 1.

**Cost-effectiveness**
The economic evaluation will examine the cost-effectiveness of hybrid AF ablation compared with (repeated) transvenous endocardial catheter ablation from a societal perspective with a time horizon up to 36 months. The outcome measure will be the incremental costs per quality-adjusted life year (QALY) gained. To calculate the QALY, a generic health-related quality of life questionnaire, the EQ-5D-5 L, will be administered at baseline and at 12 and 36 months. The Netherlands tariff will be used to value the health states as experienced by patients [25].

All resource use related to both procedures within the hospital will be recorded. In addition, medical consumption of patients during follow-up will be recorded using the iMCQ, while productivity loss will be obtained using the iPCQ [26, 27]. For the valuation of resource use, unit prices will be derived from the Pharmacotherapeutic Compass, the Netherlands guidelines for cost calculation [28], and the hospital financial department.

**Sample size calculation**
The estimated success rate (freedom from any supraventricular arrhythmia lasting > 5 min without the use of Vaughan-Williams class I or III AAD through 12 months of follow-up after the last procedure) based on literature

---

**Table 3 Exclusion criteria**

| Exclusion criteria                                                                 | Intention                          |
|----------------------------------------------------------------------------------|------------------------------------|
| Previous ablation procedure                                                      | Intolerance to heparin or warfarin |
| Longstanding persistent AF > 3 years                                             | Elevated hemic diaphragm           |
| Paroxysmal AF; AF episodes < 7 Days and successful cardioversion within 48 hours after onset represent paroxysmal AF | Significant pulmonary dysfunction as assessed by preoperative volumetric lung testing |
| AF secondary to electrolyte imbalance, thyroid disease, or other reversible or non-cardiovascular cause | Chronic obstructive pulmonary disease with a FEV1 or VC < 50% predicted |
| Presence of left atrial appendage thrombus                                        | History of cerebrovascular accident or transient ischemic attack |
| Left atrial size ≥ 60mm (PLAX-view on TTE)                                        | History of blood clotting abnormalities |
| Left ventricular ejection fraction < 40%                                           | History of thoracic radiation      |
| In need for other cardiac surgery within 12 months                                | History of pericarditis            |
| Unable to undergo TEE                                                             | History of cardiac tamponade       |
| Sick-sinus-syndrome                                                               | History of thoracotomy or cardiac surgery |
| Mitral valve insufficiency > grade I                                              | Body-mass-index > 40               |
| Carotid stenosis > 80%                                                           | Pregnancy                          |
| Active infection or sepsis                                                        | Life expectancy less than 12 months |
| Pleural adhesions                                                                | Participation in other study involving drugs or devices |

AF = Atrial fibrillation, PLAX = parasternal long axis, TTE = transthoracic echocardiography, TEE = transesophageal echocardiography, FEV1 = forced expiratory volume in 1 second, VC = vital capacity.
and our own clinical experience is 35% for single catheter ablation [2, 29] and 83% for a hybrid ablation [30, 31]. With a significance level of $\alpha = 0.05$, and a power of 90%, 20 patients per group need to be included.

**Statistical analysis**

Data analysis on the final dataset will be performed using SPSS statistical software. The per-protocol principle will be used since patients who withdraw consent before the ablation has taken place are excluded from the analysis. Univariate analysis will be applied to both continuous ($t$ test or nonparametric tests) and categorical variables (Chi-square test). Continuous variables will be reported as the mean ± standard deviation (for normally distributed variables) or median/p10–p90 (for not normally distributed variables), and categorical variables will be reported as the observed number and corresponding percentage. Depending on the number of events, univariate ($t$ test or Chi-square) or multivariate analysis (logistic regression) will be used to explore the relationship between baseline covariates and post-baseline endpoints. Kaplan-Meier survival curves will be plotted. All necessary decisions with regards to power calculations for secondary endpoints are made blind. Missing data are not computed or imputed, and the participant will be excluded for the analysis which involves the missing data.

For the cost-effectiveness analysis, any missing data will be imputed using a multiple imputation approach. As most volumes of resource use follow a skewed distribution, differences between the two groups will be analyzed with bias-corrected bootstrap analysis. In addition, bootstrap analysis will also be used to quantify the uncertainty

---

**Fig. 1** Box lesion in the setting of catheter ablation. Carto image showing a view of the posterior wall of the left atrium after wide area circumferential ablation of the pulmonary veins, and a connecting roof and inferior line (pink and red dots)

**Fig. 2** Intraoperative images of hybrid ablation. Left panel: left-sided thoracoscopic view of ablation of the left pulmonary veins using a bipolar clamp. Right panel: voltage map (Carto) after completion of the epicardial box lesion showing an isolated posterior left atrial wall. LAA left atrial appendix, PV pulmonary vein
surrounding the incremental cost-effectiveness ratio. Results of this analysis will be presented in cost-effectiveness planes and acceptability curves. Sensitivity analysis will be performed to estimate, for example, the impact of parameters on the incremental cost-effectiveness ratio. Discounting will be applied for both costs (4%) and effects (1.5%).

Ethics
Eligible candidates will be screened while considering the inclusion and exclusion criteria. Oral and written information is given to all eligible candidates. If written informed consent is obtained, the patient is enrolled in the trial and randomized to one of the treatment arms. Both the ablation strategies studied herein are currently accepted and recognized in the guidelines [19, 20, 24, 32]. Adequate clinical experience with the procedures was obtained before the present study. Full reimbursement of costs for both therapies is granted by the Dutch healthcare system. Their comparison complies with the Declaration of Helsinki for the ethical principles of medical research in human subjects. The Institutional Review Board of Maastricht University Medical Centre+ and Maastricht University (azM/UM, the Netherlands) gave full approval for the study. The study is registered in Clinicaltrials.gov under number NCT02441738. A Data Safety Monitoring Board has been formed, and its members are listed in Appendix. Adverse and serious adverse events will be reported to the Data Safety Monitoring Board and the Institutional Review Board. A clinical research monitor of the Clinical Trial Center Maastricht regularly monitors the conduct of the study.

Discussion
The aim of this single-center, randomized study is to compare the safety and efficacy between hybrid ablation and (repeated) catheter ablation for patients with nonparoxysmal AF. The results will provide new insights into the optimal interventional treatment for patients with nonparoxysmal AF, as well as associated cost-effectiveness and quality of life.

Due to the complexity of the underlying pathology, nonparoxysmal forms of AF are challenging to treat. Endocardial PVI results in single-procedure success rates of 23–48% in this patient subgroup [1–5]. However, with a second procedure and the use of AADs, outcomes can be improved to 46–69% [1–4, 33]. While PVI is still the cornerstone of the treatment of any type of AF, the appropriate substrate modification approach for nonparoxysmal AF is controversial. While the addition of CFAE ablation to PVI improved outcome in the STAR-AF I trial (74% vs. 48%, $p = 0.004$), neither the STAR-AF II trial (59% vs. 49%, $p = 0.15$) nor a large meta-analysis of 1415 patients
(29.7% vs. 31.3%, \( p = 0.17 \)) could confirm this benefit [4–6]. Furthermore, the stepwise approach consisting of PVI followed by disconnection of caval veins, CFAE ablation, and linear ablation of the roof and mitral isthmus until sinus rhythm is restored showed inconsistent results [11–15, 34]. In addition, it has been shown that full endocardial ablation of the posterior wall, which includes the application of linear lesions, does not always improve outcomes [7]. Other techniques exist, such as focal impulse and rotor modulation and isolation of low voltage areas, but without definitive positive results. In our experience, out of a total of 70 initial RF catheter ablations, performed between 2012 and 2015, 60 patients suffered from persistent AF and 10 from longstanding persistent AF. In 54 patients, only PVI was performed (77%), while in the remaining patients AT ablation (2%), CTI line (17%), and/or CFAE ablation (4%) was added. The median follow-up period was 21 months (range 15–30 months). The single-procedure success rate was disappointing, with only 21% of patients being free of supraventricular arrhythmias without AADs, and 27% with the use of an AAD. In 31/51 recurrences, a redo-procedure was performed, of which five were His bundle ablations. The pulmonary vein reconnection rate was 70% of all pulmonary veins. After the redo-procedure, the success rate without the use of AADs improved to 43%, and with the use of an AAD to 48%. The variety of reported success rates has led to different recommendations in consensus documents and guidelines. The most recent ESC guidelines do not recommend more extensive endocardial ablation during a first ablation attempt since there is not enough evidence to justify the prolonged procedure and radiation times, and the possibly higher complication rates (class IIa) [32]. On the other hand, the 2017 HRS/EHRA/ECAS expert consensus states that posterior wall isolation using a superior and inferior line in catheter ablation of nonparoxysmal AF may be considered (class IIb) [19]. In the surgical community, consensus has been achieved that additional lesions in minimally invasive off-pump procedures for nonparoxysmal AF are
recommended [20] since PVI alone does not achieve outcomes comparable to minimally invasive versions of the on-pump maze procedure (60% vs. > 80%) [35–37]. Therefore, we decided to apply the same lesion set consisting of PVI and isolation of the posterior atrial wall (a so-called box lesion) in both arms of this study.

One reason for the inconsistent results and high failure rates might be the limitations of the devices used to create transmural lesions. For example, in the STAR-AF II trial standard unipolar endocardial unipolar catheter techniques were used, which are known to not reliably produce long-lasting transmural lesions [38]. Incomplete linear lesions can be arrhythmogenic due to the possibility for re-entry at the site of gaps or by changing conduction velocity [39]. However, even if current state of the art technology is applied, as in the recent Fire and Ice trial, the limitations of endocardial ablation in reliably creating transmurality currently still remain evident [40]. Surgical bipolar and biparietal devices are better at creating transmural lesions, and modern technologies allow for an anatomical approach using thoracoscopic visualization. However, epicardial surgical ablation is unable to create efficacious isthmus lesions and lacks the opportunity of sophisticated high-density three-dimensional mapping and consecutive endocardial touch-up of gaps. A hybrid ablation, which encompasses all of these opportunities, can lead to single-procedure success rates of more than 85% freedom from AF without AADs [18, 30, 31].

Besides efficacy in terms of rhythm control, safety also determines if an approach can be recommended. The advantages of catheter ablation are that full sedation is not needed, the duration of admission is short, and recovery is fast. The complication rates of this procedure vary from 0.2% to 4% per complication, with a cumulated complication risk of 7.7% to 13% [32, 41], which we have confirmed in our center. A hybrid ablation gives a total minor complication rate of 4% and total major complication rate of 5% [42]. In our center, we have confirmed these reported complication rates [30].

Available research has shown that patients, especially those presenting with longstanding persistent AF, might benefit from a hybrid procedure compared with surgery only [43]. Furthermore, it is known that patients with failed catheter ablation show better results after a hybrid procedure compared with a redo-catheter ablation [44]. The randomized FAST trial [17] compared surgical ablation with catheter ablation. Surgical ablation was superior to catheter ablation in terms of outcome but was accompanied by more adverse events. A retrospective study of 166 patients also showed favorable results with regard to the rhythm outcome of surgical ablation over catheter ablation, with no significant differences in complication rates [45].

Consequently, a hybrid procedure combining the strengths of an epicardial and endocardial approach should overcome some of the shortcomings of each technique and enhance the outcome in the difficult to treat patient subgroup with nonparoxysmal AF. However, catheter ablation and hybrid ablation have never been compared in a trial. This gap in the literature shows the need for this study to investigate the safety and effectiveness of catheter and hybrid ablation in a randomized setting while also addressing associated cost-effectiveness to facilitate decision making in the treatment of patients with nonparoxysmal AF.

Trial status
At the time of submission, the trial is recruiting patients. The first procedure was performed on 30 January 2017.

Appendix
The members of the Data and Safety Monitoring Board for this trial are: Professor Dr. M.H. Prins, Statistician (The Netherlands), Chair; Professor F. Wellens, Cardiothoracic surgeon (Belgium); and Professor T. Gorgels, Cardiologist (Netherlands). The members declare that they have no conflict of interest with the sponsor of the study. A charter describing the roles and responsibilities of the independent Data and Safety Monitoring Board was made, including the timing of meetings, methods of providing information to and from the data and safety monitoring, frequency and format of meetings, statistical issues, and relationships with other committees.

Additional file
Additional file 1: SPIRIT checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 120 kb)

Abbreviations
AAD: Antiarrhythmic drug; AF: Atrial fibrillation; AFL: Atrial Flutter; CFAE: Complex fractionated atrial electrograms; CTI: Cavotricuspid isthmus; PVI: Pulmonary vein isolation; QALY: Quality-adjusted life year

Acknowledgements
Not applicable.

Funding
No external or internal funding is used for this study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MV: Design, informed consent, acquisition of data, analysis, interpretation, and writing. MLM: Design, hybrid ablation surgeon, interpretation, and manuscript revision. BM: Hybrid ablation surgeon, interpretation, and manuscript revision. JGLL: Catheter ablation cardiologist, and manuscript revision. KV: Manuscript revision. BE: Cost-effectiveness, and manuscript revision. BTAdG: Statistics and manuscript revision. JGM: Design and manuscript revision. HIC: Design, interpretation, and manuscript revision. LP: Design, catheter ablation cardiologist, interpretation, and manuscript revision. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Eligible candidates will be screened according to the inclusion and exclusion criteria. Oral and written information is given to all eligible candidates. If written informed consent is obtained, the patient is enrolled in the trial and randomized to one of the treatment arms. The Institutional Review Board of Maastricht University Medical Centre+ and Maastricht University (azM/UM) gave full approval for the study.

Consent for publication
Not applicable.

Competing interests
MLM is a consultant for Atricure. The remaining authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remainsneutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Cardiology, Maastricht University Medical Centre, PO Box 5800, Maastricht, The Netherlands. 2Department of Cardiothoracic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. 3Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands. 4Department of Cardiac Surgery, UZ Brussel, Brussels, Belgium. 5Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, the Netherlands.

Received: 18 September 2018 Accepted: 15 April 2019

Published online: 20 June 2019

References
1. Clarnette JA, Brooks AG, Mahajan R, et al. Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis. Europace. 2018;20(9):1366–76.
2. Teunissen C, Kassenberg W, van der Heijden JF, Hassink RJ, van Driel VJ, Zuihoff NP, et al. Five-year efficacy of pulmonary vein antrum isolation as a primary ablation strategy for atrial fibrillation: a single-centre cohort study. Europace. 2016;18(9):1335–42 PubMed PMID: 26838694.
3. Haldar SK, Jones DG, Bahrami T, De Souza A, Panikker S, Butcher C, et al. Catheter ablation versus electrophysiologically guided thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: the CASA-AF study. Heart Rhythm. 2017;14(11):1596–603 PubMed PMID: 29101964.
4. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812–22 PubMed PMID: 25946280.
5. Verma A, Mantovan R, Macle L, De Martino G, Chen J, Morillo CA, et al. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial. Eur Heart J. 2010;31(11):1344–56 PubMed PMID: 20215126. PubMed Central PMCID: PMC2879865.
6. Providencia R, Lambiasi PD, Srinivasan N, Ganesh Babu G, Bronis K, Ahsan I, et al. Is there still a role for complex fractionated atrial electrogram ablation in addition to pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation? Meta-analysis of 1415 patients. Circ Arrhythm Electrophysiol. 2015;8(5):1017–29 PubMed PMID: 26082515.
7. Tamborero D, Mont L, Bernuezo A, Matiello M, Benito B, Sitges M, et al. Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein isolation for atrial fibrillation: a prospective randomized study. Circ Arrhythm Electrophysiol. 2009;2(1):35–40 PubMed PMID: 19808442.
8. Gaita F, Caponi D, Scaglione M, Montefusco A, Corleto A, Di Monte F, et al. Long-term clinical results of 2 different ablation strategies in patients with paroxysmal and persistent atrial fibrillation. Circ Arrhythm Electrophysiol. 2008;1(4):269–75 PubMed PMID: 19088418.
9. Verma A. The techniques for catheter ablation of paroxysmal and persistent atrial fibrillation: a systematic review. Curr Opin Cardiol. 2011;26(1):17–24 PubMed PMID: 21099681.
10. Parmesanwaan R, Voskoboinik A, Gorelik A, et al. Clinical impact of rotor ablation in atrial fibrillation: a systematic review. Europace. 2018;20(7):1099–106.
11. O’Neill MD, Wright M, Knecht S, Jais P, Hocini M, Takahashi Y, et al. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. Eur Heart J. 2009;30(9):105–12 PubMed PMID: 19270341.
12. Fink T, Schluter M, Heeger CH, Lemesh C, Maurer T, Reissmann B, et al. Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation: the randomized Alster-Lost-AT trial (Ablation at St. Georg Hospital for Long- Standing Persistent Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017;10(7):e005114. https://doi.org/10.1161/CIRCEP.117.005114.
13. Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA, et al. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol. 2015;8(2):308–17 PubMed PMID: 25744570.
14. Vogler I, Willems S, Sultan A, Schreiber D, Luker J, Servatius H, et al. Pulmonary vein isolation versus defragmentation: the CHASE-AF clinical trial. J Am Coll Cardiol. 2015;66(24):2743–52 PubMed PMID: 26708836.
15. Scherr D, Khairy P, Miyaizaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol. 2015;8(1):11–8 PubMed PMID: 25252845.
16. Watanabe Y, Schill MR, Kazui T, Melby SJ, Schuesseler RB, Damiano RJ Jr. Strategies to improve the efficacy of epicardial linear ablation on the beating heart. Innovations (Phila). 2016;11(6):414–9 PubMed PMID: 27938003. PubMed Central PMCID: PMC456663.
17. Boorsma LV, Castella M, van Boven W, Bernauez A, Ylmaz A, Nadal M, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation. 2012;125(123–30 PubMed PMID: 22082673.
18. Maessen B, Pison L, Vroomen M, Luermans JG, Vernooy K, Maessen JG, et al. Three-year follow-up of hybrid ablation for atrial fibrillation. Eur J Cardiothorac Surg. 2018;53(suppl_1):106–26 PubMed PMID: 29590387.
19. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguina L, et al. 2017 HRS/ERCA/ECAS/AERPS/SOLACE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10)275–44 PubMed PMID: 28506916.
20. Badhwar V, Rankin JS, Damiano RJ Jr, Gillon AM, Baquenet FG, Edgerton JR, et al. The Society of Thoracic Surgeons. 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation. Ann Thor Surg. 2017;103(3):329–41 PubMed PMID: 28007240.
21. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: sub study of the STAR AF randomized trial. Can J Cardiol. 2013;29(10):1211–7 PubMed PMID: 23988341.
22. Steinberg JS, O’Connell H, Li S, Ziegler PD. Thirty-second gold standard definition of atrial fibrillation and its relationship with subsequent arrhythmia patterns: analysis of a large prospective device database. Circ Arrhythm Electrophysiol. 2018;11(7):e002747 PubMed PMID: 30002365.
23. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/ERCA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(8):632–96 e21 PubMed PMID: 22386883.
24. Venteegh NM, Vermeulen KM, Evers SM, de Wit GA, Pranger R, Stok EA. Dutch tariff for the fine-level version of EQ-SD. Value Health. 2016;19(4):343–52 PubMed PMID: 27325263.
25. Bouwmans C, Krol M, Severens L, Koopmanschap M, Brouwer W, Hakkaart van Roijen L. The IMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18(6):753–8 PubMed PMID: 26406901.
27. Bouwmans C, et al. Handleiding iMTA Medical Cost Questionnaire (iMCQ). Rotterdam: iMTA, Erasmus Universiteit Rotterdam; 2013. www.imta.nl

28. Hakkaart L, et al. Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg: Zorginstituut Nederland; 2015. https://www.zorginstituutnederland.nl/.../2016/...economische-evaluaties-in-de-gezond...

29. Brooks AG, Stiles MK, Laborderie J, Lau DH, Kuklik P, Shipp NJ, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm. 2010;7(6):835–46 PubMed PMID: 20206320.

30. Pison L, Gelsomino S, Luca F, Parise O, Maessen JG, Crijns HJ, et al. Effectiveness and safety of simultaneous hybrid thorascopic and endocardial catheter ablation of lone atrial fibrillation. Ann Cardiothoracic Surg. 2014;3(1):38–44 PubMed PMID: 24516796. Pubmed Central PMCID: 3904331.

31. Pison L, La Meir M, van Opstal J, Blauw Y, Maessen J, Crijns HJ. Hybrid thorascoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2012;60(1):54–61 PubMed PMID: 22742400.

32. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962 PubMed PMID: 27567408.

33. Duytschevaer M, Demolder A, Philips T, et al. Pulmonary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018;39(16):1429–37.

34. Haisaguerre M, Hocini M, Sanders P, Sacher F, Rotter M, Takahashi Y, et al. Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. J Cardiovasc Electrophysiol. 2005;16(11):1138–47 PubMed PMID: 16302893.

35. Ad N, Henry L, Friehling T, Wish M, Holmes SD. Minimally invasive stand-alone Cox-maze procedure for patients with nonparoxysmal atrial fibrillation. Ann Thorac Surg. 2013;96(3):792–8 discussion 8-9. PubMed PMID: 23891410.

36. Hu QM, Li Y, Xu CL, Han J, Zhang HB, Han W, et al. Analysis of risk factors for recurrence after video-assisted pulmonary vein isolation of lone atrial fibrillation—results of 5 years of follow-up. J Thorac Cardiovasc Surg. 2014;148(5):2174–80 PubMed PMID: 24698564.

37. Weimar T, Vosseler M, Czesla M, Boschenien M, Hemmer WB, Doll KN. Approaching a paradigm shift: endoscopic ablation of lone atrial fibrillation on the beating heart. Ann Thorac Surg. 2012;94(6):1886–92 PubMed PMID: 22959565.

38. Pison L, Vroomen M, Crijns HJ. Catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;373(9):877–8 PubMed PMID: 26308691.

39. Chae S, Oral H, Good E, Dey S, Wimmer A, Crawford T, et al. Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence. J Am Coll Cardiol. 2007;50(18):1781–7 PubMed PMID: 17964043.

40. Kuck KH, Brugada J, Furrkkanz A, Metzner A, Duytschevaer M, Brunner C, et al. Cofunction of radiofrequency ablation and cryoballoon for paroxysmal atrial fibrillation: a randomized, controlled trial. Eur Heart J. 2016;37(17):1253–61 PubMed PMID: 26850743. Pubmed Central PMCID: PMC5061588.

41. Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2013;34(15):1201–12 PubMed PMID: 23650108. Pubmed Central PMCID: PMC371364.

42. Vroomen M, Pison L. Hybrid ablation for atrial fibrillation: a systematic review. J Interv Card Electrophysiol. 2016;47(3):265–74 PubMed PMID: 27613183. Pubmed Central PMCID: PMC5110599.

43. La Meir M, Gelsomino S, Luca F, Pison L, Parise O, Colella A, et al. Minimally invasive surgical treatment of lone atrial fibrillation: early results of hybrid versus standard minimally invasive approach employing radiofrequency sources. Int J Cardiol. 2013;167(4):1469–75 PubMed PMID: 22650945.

44. Mahapatra S, LaPar DJ, Kamath S, Payne J, Bilchick KC, Mangrum JM, et al. Initial experience of sequential surgical epicardial-catheter endocardial ablation for persistent and long-standing persistent atrial fibrillation with long-term follow-up. Ann Thorac Surg. 2011;91(6):1890–8 PubMed PMID: 21619988. Pubmed Central PMCID: PMC3117201.

45. Wang J, Liu Y, Shi J, Han L, Xu C, Ma C, et al. Minimally invasive surgical versus catheter ablation for the long-lasting persistent atrial fibrillation: a randomized controlled trial. Circ Arrhythm Electrophysiol. 2011;4(7):1212–22 PubMed PMID: 21765943. Pubmed Central PMCID: PMC3135608.